Evidence map›Paper›PMID 26834537›Full record

ArticleFrontiers in neuroscience2015

Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.

Douglas G Walker, Lih-Fen Lue, Geidy Serrano, Charles H Adler, John N Caviness, Lucia I Sue, Thomas G Beach

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Differentiation and regulation of CD4Cellular and molecular life sciences : CMLS · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. The Effects ofNutrients · 2023
    Review
  13. Review
  14. Glial Cultures Differentiated from iPSCs of Patients withInternational journal of molecular sciences · 2023
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. ATP Signaling Controlling Dyskinesia Through P2X7 Receptors.Frontiers in molecular neuroscience · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Douglas G WalkerBanner Sun Health Research InstituteSun City, AZ, USA; Neurodegenerative Disease Research Center, Biodesign Institute, Arizona State UniversityTempe, AZ, USA.
Lih-Fen LueBanner Sun Health Research InstituteSun City, AZ, USA; Neurodegenerative Disease Research Center, Biodesign Institute, Arizona State UniversityTempe, AZ, USA.
Geidy SerranoBanner Sun Health Research Institute Sun City, AZ, USA.
Charles H AdlerNeurology, Mayo Clinic College of Medicine Scottsdale, AZ, USA.
John N CavinessNeurology, Mayo Clinic College of Medicine Scottsdale, AZ, USA.
Lucia I SueBanner Sun Health Research Institute Sun City, AZ, USA.
Thomas G BeachBanner Sun Health Research Institute Sun City, AZ, USA.
Banner Sun Health Research Institute · USMayo Clinic in Arizona · US

Funding

National Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8M
NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Evidence of inflammation has been consistently associated with pathology in Parkinson's disease (PD)-affected brains, and has been suggested as a causative factor. Dopaminergic neurons in the substantia nigra (SN) pars compacta, whose loss results in the clinical symptoms associated with PD, are particularly susceptible to inflammatory damage and oxidative stress. Inflammation in the striatum, where SN dopaminergic neurons project, is also a feature of PD brains. It is not known whether inflammatory changes occur first in striatum or SN. Many animal models of PD have implicated certain inflammatory molecules with dopaminergic cell neuronal loss; however, there have been few studies to validate these findings by measuring the levels of these and other inflammatory factors in human PD brain samples. This study also included samples from incidental Lewy body disease (ILBD) cases, since ILBD is considered a non-symptomatic precursor to PD, with subjects having significant loss of tyrosine hydroxylase-producing neurons. We hypothesized that there may be a progressive change in key inflammatory factors in ILBD samples intermediate between neurologically normal and PD. To address this, we used a quantitative antibody-array platform (Raybiotech-Quantibody arrays) to measure the levels of 160 different inflammation-associated cytokines, chemokines, growth factors, and related molecules in extracts of SN and striatum from clinically and neuropathologically characterized PD, ILBD, and normal control cases. Patterns of changes in inflammation and related molecules were distinctly different between SN and striatum. Our results showed significantly different levels of interleukin (IL)-5, IL-15, monokine induced by gamma interferon, and IL-6 soluble receptor in SN between disease groups. A different panel of 13 proteins with significant changes in striatum, with IL-15 as the common feature, was identified. Although the ability to detect some proteins was limited by sensitivity, patterns of expression indicated involvement of certain T-cell cytokines, vascular changes, and loss of certain growth factors, with disease progression. The results demonstrate the feasibility of profiling inflammatory molecules using diseased human brain samples, and have provided additional targets to validate in relation to PD pathology.

Indexed as

antibody arrayastrocytescytokinesdopaminergic cell lossinflammationmicrogliaParkinson's diseasepathology

Identifiers

PMID26834537
PMCPMC4712383
OpenAlexW2232736609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.